Skip To Main Content
Pamela Tenaerts on Muck Rack

Pamela Tenaerts

As seen in: MedCity News, BioSpace, Informa Connect, The Pink Sheet, BioCentury, Applied Clinical Trials, Clinical Leader, PM360, Timmerman Report, Cell & Gene and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Pamela

Contact Pamela, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Decentralized Trials Are On ‘Classic Path Of Normalization’ While ‘Solving Real Problems’

|
By Pamela Tenaerts, Kenneth A. Getz
| The Pink Sheet Verified
Decentralized trial tools are settling into routine use as sponsors and sites apply them selectively to address protocol-specific operational needs, say Pamela Tenaerts and Kenneth Getz.
Open in Who Shared Issue with article?

How digital can ease the burden of cell and gene therapy long-term follow-up

|
By Pamela Tenaerts
| Cell & Gene Therapy Review Verified
Cell and gene therapies (CGTs) have the potential to offer curative possibilities for many conditions, some more common and some with few, or even no, effective treatments. The clinical potential of these groundbreaking therapies is immense,1 however, their pace of release has not been nearly as groundbreaking. By the end of 2023, only a handful had received authorization in major pharmaceutical markets: 18 in the U.S., 17 in the EU, and fewer in other countries.
Open in Who Shared Issue with article?

Digital solutions hold the key to managing long-term follow-up for gene and cell therapies

|
By Pamela Tenaerts
| Informa Connect Verified
As approvals accelerate, technology is critical to easing patient burden, improving data, and lowering costs in long-term cell and gene therapy trials. Cell and gene therapies (CGTs) are on the frontiers in medicine, offering the ability to treat both common and rare conditions by altering the body at the cellular or genetic level.
Open in Who Shared Issue with article?
See all 13 licensed articles (15 Total)